Skip to content
WeighLab
Menu
Ranked #34 · Grade C

Direct Meds review

The widest set of routes on this board — sublingual and injection on both semaglutide and tirzepatide, every SKU priced in the open — sold well above the median, on a plan that only ever bills against a 90-day supply.

Visit Direct Meds Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$249/mo (sublingual, 90-day supply billed monthly)
Tirzepatide
$299/mo (sublingual, 90-day supply billed monthly)
Coverage
Not disclosed
Brand-name
Compounded only

Semaglutide · modeled / year

$2,988

Tirzepatide · modeled / year

$3,588

The Index scorecard

Direct Meds scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month62/100
Price Transparency78/100
Nationwide Access60/100
Formulation Options96/100
Clinical Oversight68/100
Contract Flexibility66/100

Where the value is

  • Sublingual AND injection on BOTH molecules — four GLP-1 SKUs, the widest formulation range of any provider on this board
  • Every price is published per SKU in a public shop, with no quiz, intake or email capture in front of it
  • Each product page prints a per-day equivalent beside the monthly rate ($8.03/day at $249), which is unusually concrete for this category
  • Free shipping, no monthly membership fee and no hidden fees are stated on every product page
  • Sermorelin and NAD+ sit in the same catalogue for anyone already buying a GLP-1 there

The tradeoffs

  • $249/mo sublingual is well above this board's ~$144 median, and the injection route is $297 — the cheapest thing here is dearer than most rows' headline price
  • The only purchasable option on every product page is a 90-DAY SUPPLY billed monthly, so three months is the smallest unit sold — there is no month-to-month rate to compare against the rows beside it
  • Every headline figure is framed "AS LOW AS", yet the only available option shows "0% OFF" — the framing implies a cheaper tier that is not actually on sale
  • No state list is published, so coverage cannot be checked before signing up
  • The compounding pharmacy is never named, and we found no LegitScript listing — the same unnamed-clinical-layer gap that caps several rows on this board
  • No FDA-approved brand-name route (no Wegovy, Ozempic, Mounjaro or Zepbound)
  • The site's own social proof does not agree with itself: the weight-loss page says "4.6" and "over 250,000+ happy customers", while the product pages say "4.5" and "100,000+ Happy Customers" — so we cite no customer count or rating for it at all

The bottom line

Best for: Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold. The widest set of routes on this board — sublingual and injection on both semaglutide and tirzepatide, every SKU priced in the open — sold well above the median, on a plan that only ever bills against a 90-day supply.

Ranked #34 of 34 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Visit Direct Meds

Compare with other providers

All 33 other providers we've modeled, in Cost-Efficiency Index order.

Every other program we track (30)

Pricing, states and verification reflect Direct Meds's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Direct Meds's site. Not medical advice; see our disclosure.

← Back to the value leaderboard